We are live on
!
Find out more
Vestal Point Capital Portfolio holdings
AUM
$4.28B
Turnover
40.4%
1-Year Est. Return
239%
This Fund
S&P 500
This Quarter
Est. Return
+5.05%
1 Year Est. Return
+239%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$3.58B
AUM Growth
+$636M
(+22%)
Cap. Flow
+$858M
Cap. Flow
% of AUM
23.98%
Top 10 Holdings %
Top 10 Hldgs %
40.4%
Holding
113
New
37
Increased
33
Reduced
14
Closed
23
Avg Time Held Equity + Options
0.6
years
Top 10 Avg Time Held Equity + Options
0.1
years
Top 20 Avg Time Held Equity + Options
0.3
years
Avg Time Held Equity only
0.6
years
Top 10 Avg Time Held Equity only
0.1
years
Top 20 Avg Time Held Equity only
0.3
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Revolution Medicines
RVMD
|
+$210M |
| 2 |
Neurocrine Biosciences
NBIX
|
+$166M |
| 3 |
Repligen
RGEN
|
+$118M |
| 4 |
Arrowhead Research
ARWR
|
+$87M |
| 5 |
Immunocore
IMCR
|
+$70.6M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Arcellx
ACLX
|
+$191M |
| 2 |
Terns Pharmaceuticals
TERN
|
+$144M |
| 3 |
DexCom
DXCM
|
+$84.6M |
| 4 |
Merck
MRK
|
+$81.6M |
| 5 |
Tyra Biosciences
TYRA
|
+$76.8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
1
Revolution Medicines
RVMD
$38.2B
| $231M | 6.46% |
2,375,000
+2,080,000
| +705% | +$210M |
2025 Q2
3 quarters
|
|
2
BioMarin Pharmaceuticals
BMRN
$10.6B
| $202M | 5.65% |
3,575,000
+575,000
| +19% | +$33.5M |
2025 Q2
3 quarters
|
|
3
Abivax
ABVX
$7.69B
| $167M | 4.67% |
1,500,000
-400,000
| -21% | -$47.3M |
2025 Q3
2 quarters
|
|
|
4
Neurocrine Biosciences
NBIX
$13.8B
| $165M | 4.6% |
+1,250,000
| New | +$166M |
2026 Q1
0 quarters
|
|
|
5
Arrowhead Research
ARWR
$7.9B
| $143M | 3.99% |
2,275,000
+1,375,000
| +153% | +$87M |
2025 Q4
1 quarter
|
|
6
Enliven Therapeutics
ELVN
$2.74B
| $127M | 3.56% |
3,250,000
-580,000
| -15% | -$16.1M |
2025 Q2
3 quarters
|
|
|
7
Repligen
RGEN
$11.1B
| $109M | 3.05% |
925,000
+842,000
| +1,014% | +$118M |
2025 Q3
2 quarters
|
|
8
Bicara Therapeutics
BCAX
$1.11B
| $108M | 3.02% |
5,425,000
+1,850,000
| +52% | +$31.8M |
2024 Q3
6 quarters
|
|
9
Nurix Therapeutics
NRIX
$2.67B
| $101M | 2.82% |
6,500,000
+1,810,000
| +39% | +$30M |
2024 Q2
7 quarters
|
|
10
DELISTED
Apogee Therapeutics
APGE
| $92.6M | 2.59% |
1,100,000
+550,000
| +100% | +$39.9M |
2025 Q3
2 quarters
|
|
11
Ascendis Pharma A/S
ASND
$14.8B
| $85.8M | 2.4% |
375,000
+200,000
| +114% | +$44.8M |
2023 Q4
9 quarters
|
|
|
12
Immunocore
IMCR
$1.52B
| $83.4M | 2.33% |
2,766,868
+2,181,868
| +373% | +$70.6M |
2025 Q4
1 quarter
|
|
13
Taysha Gene Therapies
TSHA
$1.18B
| $80.5M | 2.25% |
18,000,000
+4,250,000
| +31% | +$19.8M |
2025 Q2
3 quarters
|
|
14
Dyne Therapeutics
DYN
$2.66B
| $72.5M | 2.03% |
4,000,000
+3,880,000
| +3,233% | +$66.9M |
2025 Q1
4 quarters
|
|
15
Sanofi
SNY
$97.3B
| $67.5M | 1.89% |
+1,400,000
| New | +$65.3M |
2026 Q1
0 quarters
|
|
16
BioCryst Pharmaceuticals
BCRX
$1.99B
| $66.9M | 1.87% |
7,025,000
+4,775,000
| +212% | +$37.1M |
2025 Q4
1 quarter
|
|
17
Scholar Rock
SRRK
$4.86B
| $65.1M | 1.82% |
1,324,422
+624,422
| +89% | +$28M |
2025 Q1
4 quarters
|
|
18
Immatics
IMTX
$1.02B
| $60.8M | 1.7% |
6,175,000
+50,000
| +0.8% | +$490K |
2023 Q4
9 quarters
|
|
19
Bristol-Myers Squibb
BMY
$122B
| $60.6M | 1.7% |
1,000,000
+750,000
| +300% | +$43.7M |
2025 Q4
1 quarter
|
|
20
Alcon
ALC
$32B
| $60.3M | 1.69% |
800,000
-305,000
| -28% | -$24.3M |
2025 Q2
3 quarters
|
|
21
Monte Rosa Therapeutics
GLUE
$831M
| $59.3M | 1.66% |
3,603,465
+2,828,465
| +365% | +$54.1M |
2025 Q3
2 quarters
|
|
22
Vera Therapeutics
VERA
$2.01B
| $55M | 1.54% |
1,368,159
+818,159
| +149% | +$35.2M |
2024 Q4
5 quarters
|
|
|
23
DELISTED
Terns Pharmaceuticals
TERN
| $52.7M | 1.47% |
1,000,000
-3,500,000
| -78% | -$144M |
2025 Q4
1 quarter
|
|
24
Globus Medical
GMED
$10.3B
| $52.6M | 1.47% |
610,520
-664,480
| -52% | -$59.6M |
2024 Q4
5 quarters
|
|
25
Boston Scientific
BSX
$64.3B
| $50.2M | 1.4% |
+800,000
| New | +$64M |
2026 Q1
0 quarters
|
|
Similar funds
HCC
GHC
Vestal Point Capital's Q1 2026 Portfolio in Review
As of Q1 2026, Vestal Point Capital held 113 positions worth $3.58B, up 22% from $2.94B the previous quarter. Its ten largest holdings account for 40% of the portfolio.
Vestal Point Capital deployed $858M of net new capital in Q1 2026, opening 37 new positions and adding to 33 existing holdings. Its largest new stake was Neurocrine Biosciences: 1,250,000 shares worth $165M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 93% a quarter earlier.
On the sell side, the largest reduction was Terns Pharmaceuticals, an estimated $144M trimmed.
- Vestal Point Capital's largest Q1 2026 buy was Neurocrine Biosciences: 1,250,000 shares worth $165M.
- Vestal Point Capital added most to Revolution Medicines in Q1 2026, an estimated $210M increase.
- Vestal Point Capital's biggest Q1 2026 reduction was Terns Pharmaceuticals, cutting an estimated $144M.
- Vestal Point Capital fully exited Arcellx in Q1 2026, selling an estimated $191M.
- Vestal Point Capital's ten largest holdings make up 40% of its $3.58B portfolio in Q1 2026.
- Vestal Point Capital opened 37 new positions and closed 23 in Q1 2026.
- Vestal Point Capital's portfolio value rose 22% quarter-over-quarter to $3.58B.
Based on Vestal Point Capital's 13F filing for Q1 2026, filed 15 May 2026.